Eudragit NE30D based metformin/gliclazide extended release tablets: Formulation, characterisation and in vitro release studies

22Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Metformin/Gliclazide extended release tablets were formulated with Eudragit NE30D by wet granulation technique. Two batches were prepared in order to study influence of drug polymer ratio on the tablet formation and in vitro drug release. The formulated tablets were characterized by disintegration time, hardness, friability, thickness, weight variation, and in vitro drug release. The percentage of polymer, with respect to Metformin/Gliclazide, required to produce tablets with acceptable qualities was 9 to 13.45. The percentage of polymer below this range released the drug immediately and above this range produced granules not suitable for tablet formation. The quantity of Metformin/Gliclazide present in the tablets and the release medium were estimated by a validated HPLC method. The formulated tablets had acceptable physicochemical characters and released the drug over 6-8 h. The data obtained from in vitro release studies were fitted with various kinetic models and was found to follow Higuchi kinetics. © 2002 Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Arno, E. A., Anand, P., Bhaskar, K., Ramachandran, S., Saravanan, M., & Vinod, R. (2002). Eudragit NE30D based metformin/gliclazide extended release tablets: Formulation, characterisation and in vitro release studies. Chemical and Pharmaceutical Bulletin, 50(11), 1495–1498. https://doi.org/10.1248/cpb.50.1495

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free